$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
Page: < prev 1 ... 3 4 5 6 7 8 9 10 11 ... 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 290.02 | 13,974 | 4,052,739 | 1,132,614 | 1.1 M to 1.1 M (-1.22 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 289.07 | 15,131 | 4,373,918 | 1,146,588 | 1.2 M to 1.1 M (-1.30 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 288.11 | 26,028 | 7,498,927 | 1,161,719 | 1.2 M to 1.2 M (-2.19 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 287.16 | 18,041 | 5,180,654 | 1,187,747 | 1.2 M to 1.2 M (-1.50 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 286.24 | 7,611 | 2,178,573 | 1,205,788 | 1.2 M to 1.2 M (-0.63 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 285.18 | 23,903 | 6,816,658 | 1,213,399 | 1.2 M to 1.2 M (-1.93 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 284.20 | 16,845 | 4,787,349 | 1,237,302 | 1.3 M to 1.2 M (-1.34 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 282.87 | 9,357 | 2,646,815 | 1,254,147 | 1.3 M to 1.3 M (-0.74 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 282.13 | 8,397 | 2,369,046 | 1,263,504 | 1.3 M to 1.3 M (-0.66 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 281.11 | 5,623 | 1,580,682 | 1,271,901 | 1.3 M to 1.3 M (-0.44 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.82 | 90 | 26,534 | 1,120,324 | 1.1 M to 1.1 M (-0.01 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 293.85 | 2,500 | 734,625 | 1,120,414 | 1.1 M to 1.1 M (-0.22 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 292.13 | 6,000 | 1,752,780 | 1,122,914 | 1.1 M to 1.1 M (-0.53 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 291.12 | 3,700 | 1,077,144 | 1,128,914 | 1.1 M to 1.1 M (-0.33 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 290.02 | 13,974 | 4,052,739 | 1,132,614 | 1.1 M to 1.1 M (-1.22 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 289.07 | 15,131 | 4,373,918 | 1,146,588 | 1.2 M to 1.1 M (-1.30 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 288.11 | 26,028 | 7,498,927 | 1,161,719 | 1.2 M to 1.2 M (-2.19 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 287.16 | 18,041 | 5,180,654 | 1,187,747 | 1.2 M to 1.2 M (-1.50 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 286.24 | 7,611 | 2,178,573 | 1,205,788 | 1.2 M to 1.2 M (-0.63 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 285.18 | 23,903 | 6,816,658 | 1,213,399 | 1.2 M to 1.2 M (-1.93 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 284.20 | 16,845 | 4,787,349 | 1,237,302 | 1.3 M to 1.2 M (-1.34 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.87 | 9,357 | 2,646,815 | 1,254,147 | 1.3 M to 1.3 M (-0.74 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.13 | 8,397 | 2,369,046 | 1,263,504 | 1.3 M to 1.3 M (-0.66 %) |
| Mar 30 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 281.11 | 5,623 | 1,580,682 | 1,271,901 | 1.3 M to 1.3 M (-0.44 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 270.23 | 2,800 | 756,644 | 1,277,524 | 1.3 M to 1.3 M (-0.22 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 275.56 | 3,844 | 1,059,253 | 1,280,324 | 1.3 M to 1.3 M (-0.30 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 275.00 | 12,066 | 3,318,150 | 1,284,168 | 1.3 M to 1.3 M (-0.93 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 273.19 | 2,700 | 737,613 | 1,296,234 | 1.3 M to 1.3 M (-0.21 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 272.13 | 3,050 | 829,997 | 1,298,934 | 1.3 M to 1.3 M (-0.23 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 271.15 | 6,063 | 1,643,982 | 1,301,984 | 1.3 M to 1.3 M (-0.46 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 270.13 | 9,574 | 2,586,225 | 1,308,047 | 1.3 M to 1.3 M (-0.73 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 269.10 | 1,539 | 414,145 | 1,317,621 | 1.3 M to 1.3 M (-0.12 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 268.13 | 6,764 | 1,813,631 | 1,319,160 | 1.3 M to 1.3 M (-0.51 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 288.60 | 1,000 | 288,600 | 1,325,924 | 1.3 M to 1.3 M (-0.08 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 286.04 | 1,400 | 400,456 | 1,326,924 | 1.3 M to 1.3 M (-0.11 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 283.44 | 52 | 14,739 | 1,328,324 | 1.3 M to 1.3 M (0.00 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 283.29 | 1,548 | 438,533 | 1,328,376 | 1.3 M to 1.3 M (-0.12 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 282.00 | 3,500 | 987,000 | 1,329,924 | 1.3 M to 1.3 M (-0.26 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 281.01 | 6,306 | 1,772,049 | 1,333,424 | 1.3 M to 1.3 M (-0.47 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 280.00 | 9,465 | 2,650,200 | 1,339,730 | 1.3 M to 1.3 M (-0.70 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 279.00 | 3,668 | 1,023,372 | 1,349,195 | 1.4 M to 1.3 M (-0.27 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 278.00 | 14,152 | 3,934,256 | 1,352,863 | 1.4 M to 1.4 M (-1.04 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 276.96 | 8,195 | 2,269,687 | 1,367,015 | 1.4 M to 1.4 M (-0.60 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 275.95 | 37,666 | 10,393,933 | 1,375,210 | 1.4 M to 1.4 M (-2.67 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 274.86 | 3,579 | 983,724 | 1,412,876 | 1.4 M to 1.4 M (-0.25 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 273.89 | 11,869 | 3,250,800 | 1,416,455 | 1.4 M to 1.4 M (-0.83 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 272.79 | 8,638 | 2,356,360 | 1,428,324 | 1.4 M to 1.4 M (-0.60 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 271.70 | 7,764 | 2,109,479 | 1,436,962 | 1.4 M to 1.4 M (-0.54 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 270.70 | 40,598 | 10,989,879 | 1,444,726 | 1.5 M to 1.4 M (-2.73 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.23 | 2,800 | 756,644 | 1,277,524 | 1.3 M to 1.3 M (-0.22 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.56 | 3,844 | 1,059,253 | 1,280,324 | 1.3 M to 1.3 M (-0.30 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.00 | 12,066 | 3,318,150 | 1,284,168 | 1.3 M to 1.3 M (-0.93 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 273.19 | 2,700 | 737,613 | 1,296,234 | 1.3 M to 1.3 M (-0.21 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 272.13 | 3,050 | 829,997 | 1,298,934 | 1.3 M to 1.3 M (-0.23 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 271.15 | 6,063 | 1,643,982 | 1,301,984 | 1.3 M to 1.3 M (-0.46 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.13 | 9,574 | 2,586,225 | 1,308,047 | 1.3 M to 1.3 M (-0.73 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 269.10 | 1,539 | 414,145 | 1,317,621 | 1.3 M to 1.3 M (-0.12 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 268.13 | 6,764 | 1,813,631 | 1,319,160 | 1.3 M to 1.3 M (-0.51 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 288.60 | 1,000 | 288,600 | 1,325,924 | 1.3 M to 1.3 M (-0.08 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 286.04 | 1,400 | 400,456 | 1,326,924 | 1.3 M to 1.3 M (-0.11 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 283.44 | 52 | 14,739 | 1,328,324 | 1.3 M to 1.3 M (0.00 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 283.29 | 1,548 | 438,533 | 1,328,376 | 1.3 M to 1.3 M (-0.12 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 282.00 | 3,500 | 987,000 | 1,329,924 | 1.3 M to 1.3 M (-0.26 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 281.01 | 6,306 | 1,772,049 | 1,333,424 | 1.3 M to 1.3 M (-0.47 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 280.00 | 9,465 | 2,650,200 | 1,339,730 | 1.3 M to 1.3 M (-0.70 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 279.00 | 3,668 | 1,023,372 | 1,349,195 | 1.4 M to 1.3 M (-0.27 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 278.00 | 14,152 | 3,934,256 | 1,352,863 | 1.4 M to 1.4 M (-1.04 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 276.96 | 8,195 | 2,269,687 | 1,367,015 | 1.4 M to 1.4 M (-0.60 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 275.95 | 37,666 | 10,393,933 | 1,375,210 | 1.4 M to 1.4 M (-2.67 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 274.86 | 3,579 | 983,724 | 1,412,876 | 1.4 M to 1.4 M (-0.25 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 273.89 | 11,869 | 3,250,800 | 1,416,455 | 1.4 M to 1.4 M (-0.83 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 272.79 | 8,638 | 2,356,360 | 1,428,324 | 1.4 M to 1.4 M (-0.60 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 271.70 | 7,764 | 2,109,479 | 1,436,962 | 1.4 M to 1.4 M (-0.54 %) |
| Mar 25 2015 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 270.70 | 40,598 | 10,989,879 | 1,444,726 | 1.5 M to 1.4 M (-2.73 %) |
| Mar 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 973 | 9,557 | 4,003 | |
| Mar 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 305.36 | 973 | 297,115 | 962 | 1.9 K to 962 (-50.28 %) |
| Mar 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 973 | 9,557 | 1,935 | 962 to 1.9 K (+101.14 %) |
| Mar 18 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 3,500 | 36,400 | 203 | |
| Mar 18 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 288.26 | 2,500 | 720,640 | 18,796 | 21.3 K to 18.8 K (-11.74 %) |
| Mar 18 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 283.50 | 1,000 | 283,500 | 21,296 | 22.3 K to 21.3 K (-4.49 %) |
| Mar 18 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 3,500 | 36,400 | 22,296 | 18.8 K to 22.3 K (+18.62 %) |
| Mar 16 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 5,000 | 43,334 | 5,971 | |
| Mar 16 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 285.99 | 5,000 | 1,429,938 | 18,796 | 23.8 K to 18.8 K (-21.01 %) |
| Mar 16 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 5,000 | 43,334 | 23,796 | 18.8 K to 23.8 K (+26.60 %) |
| Mar 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 9,145 | |
| Mar 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 263.25 | 158 | 41,594 | 2,166 | 2.3 K to 2.2 K (-6.80 %) |
| Mar 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 261.25 | 233 | 60,871 | 2,324 | 2.6 K to 2.3 K (-9.11 %) |
| Mar 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Feb 26 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 632 | 13,588 | 9,536 | |
| Feb 26 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 222.50 | 632 | 140,620 | 2,166 | 2.8 K to 2.2 K (-22.59 %) |
| Feb 26 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 632 | 13,588 | 2,798 | 2.2 K to 2.8 K (+29.18 %) |
| Feb 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 974 | 9,567 | 4,976 | |
| Feb 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 216.00 | 974 | 210,384 | 962 | 1.9 K to 962 (-50.31 %) |
| Feb 24 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 974 | 9,567 | 1,936 | 962 to 1.9 K (+101.25 %) |
| Feb 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 5,294 | 45,882 | 35,425 | |
| Feb 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 3,500 | 36,400 | 3,703 | |
| Feb 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 212.12 | 2,000 | 424,242 | 18,796 | 20.8 K to 18.8 K (-9.62 %) |
| Feb 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 210.95 | 1,146 | 241,749 | 20,796 | 21.9 K to 20.8 K (-5.22 %) |
| Feb 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 204.62 | 1,500 | 306,930 | 21,942 | 23.4 K to 21.9 K (-6.40 %) |
| Feb 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 3,500 | 36,400 | 23,442 | 19.9 K to 23.4 K (+17.55 %) |
| Feb 19 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 5,294 | 45,882 | 19,942 | 14.6 K to 19.9 K (+36.14 %) |
| Feb 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 233 | 5,010 | 10,168 | |
| Feb 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 195.52 | 233 | 45,556 | 2,166 | 2.4 K to 2.2 K (-9.71 %) |
| Feb 12 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 233 | 5,010 | 2,399 | 2.2 K to 2.4 K (+10.76 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | M | 37.69 | 9,847 | 371,133 | 92,028 | |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 208.08 | 200 | 41,616 | 1,264 | 1.5 K to 1.3 K (-13.66 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 205.87 | 800 | 164,698 | 1,464 | 2.3 K to 1.5 K (-35.34 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 202.49 | 793 | 160,577 | 2,264 | 3.1 K to 2.3 K (-25.94 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 201.50 | 1,207 | 243,213 | 3,057 | 4.3 K to 3.1 K (-28.31 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 200.07 | 6,847 | 1,369,859 | 4,264 | 11.1 K to 4.3 K (-61.62 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Buy | M | 37.69 | 9,847 | 371,133 | 11,111 | 1.3 K to 11.1 K (+779.03 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 3,500 | 36,400 | 7,203 | |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 4,000 | 34,667 | 10,971 | |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 208.10 | 953 | 198,317 | 14,648 | 15.6 K to 14.6 K (-6.11 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 207.01 | 2,379 | 492,466 | 15,601 | 18 K to 15.6 K (-13.23 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 206.03 | 1,068 | 220,041 | 17,980 | 19 K to 18 K (-5.61 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 204.20 | 3,100 | 633,009 | 19,048 | 22.1 K to 19 K (-14.00 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 3,500 | 36,400 | 22,148 | 18.6 K to 22.1 K (+18.77 %) |
| Feb 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 4,000 | 34,667 | 18,648 | 14.6 K to 18.6 K (+27.31 %) |
| Jan 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 973 | 9,557 | 5,950 | |
| Jan 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 151.32 | 973 | 147,234 | 1,465 | 2.4 K to 1.5 K (-39.91 %) |
| Jan 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 973 | 9,557 | 2,438 | 1.5 K to 2.4 K (+66.42 %) |
| Jan 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 233 | 5,010 | 10,401 | |
| Jan 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 150.01 | 233 | 34,952 | 2,166 | 2.4 K to 2.2 K (-9.71 %) |
| Jan 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 233 | 5,010 | 2,399 | 2.2 K to 2.4 K (+10.76 %) |
| Jan 07 2015 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 176.49 | 146 | 25,767 | 1,264 | 1.4 K to 1.3 K (-10.35 %) |
| Jan 07 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 176.49 | 461 | 81,360 | 491,032 | 491.5 K to 491 K (-0.09 %) |
| Jan 07 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 172.63 | 664 | 114,627 | 14,648 | 15.3 K to 14.6 K (-4.34 %) |
| Jan 07 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 176.49 | 141 | 24,884 | 17,264 | 17.4 K to 17.3 K (-0.81 %) |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,623 | 0 | 6,490 | |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 158.71 | 376 | 59,675 | 15,312 | 15.7 K to 15.3 K (-2.40 %) |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,623 | 0 | 15,688 | 14.1 K to 15.7 K (+11.54 %) |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 0.00 | 4,868 | 0 | 19,471 | |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 0.00 | 4,868 | 0 | 491,493 | 486.6 K to 491.5 K (+1.00 %) |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 31.90 | 1,000 | 31,900 | 14,875 | |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 5,192 | |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 158.35 | 500 | 79,175 | 17,405 | 17.9 K to 17.4 K (-2.79 %) |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 154.45 | 500 | 77,225 | 17,905 | 18.4 K to 17.9 K (-2.72 %) |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 31.90 | 1,000 | 31,900 | 18,405 | 17.4 K to 18.4 K (+5.75 %) |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 17,405 | 16.1 K to 17.4 K (+8.06 %) |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 2,596 | |
| Jan 05 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 9,411 | 8.8 K to 9.4 K (+7.41 %) |
| Dec 15 2014 | ICPT | INTERCEPT PHARMACE ... | Benatti Luca | Director | Buy | P | 139.86 | 800 | 111,888 | 1,292 | 492 to 1.3 K (+162.60 %) |
| Dec 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 233 | 5,010 | 10,634 | |
| Dec 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 144.16 | 233 | 33,589 | 2,166 | 2.4 K to 2.2 K (-9.71 %) |
| Dec 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 233 | 5,010 | 2,399 | 2.2 K to 2.4 K (+10.76 %) |
| Nov 20 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 21.50 | 31 | 667 | 51,891 | |
| Nov 20 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 6,685 | 57,937 | 36,314 | |
| Nov 20 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 21.50 | 31 | 667 | 486,625 | 486.6 K to 486.6 K (+0.01 %) |
| Nov 20 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 6,685 | 57,937 | 486,594 | 479.9 K to 486.6 K (+1.39 %) |